VivoSeq
Oncology

Hematological Malignancy

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Hematological Malignancy is an early-stage landscape with 0 programs across 4 companies. The most active players are Johnson & Johnson, Acrotech Biopharma Inc., Timmune Biotech Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

43/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalA

Acrotech Biopharma Inc.

0 programs

PreclinicalT

Timmune Biotech Inc.

0 programs

PreclinicalM

Mirror Biologics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Terminated4 · 27%
Unknown status3 · 20%
Completed3 · 20%
Recruiting3 · 20%
Not yet recruiting1 · 7%
Available1 · 7%

Clinical Trials

Trial Activity

15 trials

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Recruiting·AAcrotech Biopharma Inc.·Phase 1·NCT07036133·24 enrolled
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Recruiting·—·Phase 1·NCT04227015·72 enrolled
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
Recruiting·UUniversity of Nebraska·Preclinical·NCT07292272·180 enrolled
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT07117175·18 enrolled
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00597519·28 enrolled
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Completed·VVirginia Commonwealth University·Phase 2·NCT02593123·31 enrolled
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Completed·MMirror Biologics, Inc.·Phase 1/2·NCT00558675·6 enrolled
Stem Cell Transplant for Hematological Malignancy
Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00176930·330 enrolled
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 4·NCT02895529·61 enrolled
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Terminated·MMedical College of Wisconsin·Phase 1·NCT03588936·2 enrolled
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Terminated·UUniversity Health Network, Toronto·Phase 1·NCT00963495·11 enrolled
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
Unknown status·—·Phase 1·NCT04226989·72 enrolled
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Unknown status·ZZhejiang University·Phase 1·NCT04599556·81 enrolled
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Unknown status·TTimmune Biotech Inc.·Phase 1·NCT04191941·9 enrolled
Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Available·PPeking University·N/A·NCT01250808

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)